Genor Biopharma Holdings Limited ((DE:67N0)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genor Biopharma Holdings Limited is initiating a Phase I, first-in-human study titled ‘A Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants With Advanced Solid Tumors.’ The study aims to assess the safety and effectiveness of the GB268 antibody in treating advanced solid tumors, marking a significant step in cancer treatment research.
The intervention being tested is GB268, a trispecific antibody targeting PD-1, CTLA-4, and VEGF. This drug is designed to enhance the immune system’s ability to fight cancer by blocking these pathways, potentially offering a new therapeutic option for patients with advanced solid tumors.
This open-label study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. It will include a dose-escalation stage followed by a dose-expansion stage to determine the optimal dosing and gather preliminary efficacy data.
The study is set to begin on March 16, 2025, with primary completion and estimated study completion dates yet to be announced. The latest update was submitted on April 27, 2025, indicating ongoing preparations for recruitment.
This study could influence Genor Biopharma’s stock performance positively if successful, as it represents a novel approach in cancer treatment. Investors should watch for updates, considering the competitive landscape in oncology therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.